These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1766521)

  • 1. Prescription of calcium carbonate to nondialyzed patients with a supranormal serum 1,25(OH)2D3 concentration.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nephron; 1991; 59(4):683-4. PubMed ID: 1766521
    [No Abstract]   [Full Text] [Related]  

  • 2. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitriol and calcium carbonate therapy in early chronic renal failure.
    Brown CB
    Nephrol Dial Transplant; 1995 Nov; 10(11):2158-9. PubMed ID: 8643194
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium carbonate treatment of uremic acidosis.
    Berlyne GM
    Isr J Med Sci; 1971 Nov; 7(11):1235-9. PubMed ID: 5159605
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of relationship between parathyroid hormone and 1,25-dihydroxyvitamin D in chronic renal failure.
    Rudnicki M; McNair P; Transbøl I; Nielsen B
    Nephron; 1991; 58(2):144-9. PubMed ID: 1865969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcitriol and calcium carbonate therapy in early chronic renal failure.
    Bianchi ML; Colantonio G; Campanini F; Rossi R; Valenti G; Ortolani S; Buccianti G
    Nephrol Dial Transplant; 1994; 9(11):1595-9. PubMed ID: 7870349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the effect of vitamin D and calcium carbonate in renal osteomalacia.
    Eastwood JB; Bordier P; de Wardener HE
    Q J Med; 1971 Oct; 40(160):569-70. PubMed ID: 5157413
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration.
    Takamoto S; Onishi T; Morimoto S; Imanaka S; Tsuchiya H; Seino Y; Yokokawa T; Iida N; Kumahara Y
    Nephron; 1985; 40(3):286-91. PubMed ID: 3839293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin in chronic renal failure.
    Franck H; Keck E; Issa S; Krüskemper HL; von Lilienfeld-Toal H
    Exp Clin Endocrinol; 1988 May; 91(2):202-6. PubMed ID: 3409970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure.
    Lu KC; Lin SH; Yu FC; Chyr SH; Shieh SD
    Miner Electrolyte Metab; 1995; 21(6):398-402. PubMed ID: 8592483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
    Takahashi S; Okada K; Kinosita Y; Yanai M; Kuno T; Nagura Y
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The radiographic spectrum of renal osteodystrophy.
    Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL
    Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium carbonate 1250 mg/1260 mg: an effective phosphate binder.
    Taylor JE; Henderson IS; Stewart WK; Mactier RA
    Scott Med J; 1990 Apr; 35(2):45-7. PubMed ID: 2374904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.